Media Room
Third quarter 2024 results
Third quarter 2024 results were reviewed by management during a conference call with the financial community on Friday October 25, 2024. The presentation was followed by a Q&A session.
Press releases
November 15, 2024
Communiqué de presse - Sanofi renforce la bioproduction d’anticorps en France avec un investissement de plus de 40 millions d’euros sur son site de Lyon Gerland
November 15, 2024
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
November 14, 2024
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Contact Our Media Team
You are a journalist and have a question about Sanofi, please contact the Global Media relations team. Please note the contact details are only for journalists.
Publications
Half Year 2024 Financial Report XBRL Package
Half Year 2024 Financial Report
Declaration of extra-financial performance 2023 (ESG Report)
Half Year 2023 Financial Report